Become A Featured Company

Cannabis Traceability: Problems & Solutions

Ryan Allway

April 3rd, 2019

Exclusive, News, Top Story

The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a 34.6 percent compound annual growth rate over the time period. Despite these rapid growth rates, the industry has faced several high profile traceability issues in Washington, Nevada, Michigan, Oregon, and Pennsylvania, including diversion into the black market, product recalls from contamination, and lost revenue from traceability issues.

Helix TCS Inc.(OTCQB: HLIX), a leading provider of critical infrastructure services for the legal cannabis industry, has become an evident leader in providing traceability solutions—solutions that have a growing need as states continue to experience issues.

Click here to receive an investor fact sheet and corporate updates

Supply Chain Integrity

Oregon’s legal cannabis industry generated about $250 million in revenue in 2016, which was nearly six times more than official expectations. While the growth has been impressive, there is between 132 to 900 tons more cannabis grown than sold in the state. The excess cannabis often flows out of the state without a trace in what regulators call diversion. Growers are selling excess production into the black market to grow their revenue.

Nevada’s cannabis industry experienced a related setback when an audit revealed that discrepancies in data entry by marijuana businesses may have cost the state more than $500,000 in tax revenue over a six month period. In addition, the audit found that high-potency products meant for medical marijuana patients were sold to recreational customers in 43 percent of cases, threatening the health and safety of consumers.

Many states require cannabis businesses to track their products across the supply chain to reduce diversion. By establishing a chain of custody, regulators can ensure that no cannabis product goes missing or moves out of state. The technology used to trace cannabis throughout the supply chain ranges from conventional labels to genetic biomarkers that are absorbed into cannabis plants through water and soil.

Click here to receive an investor fact sheet and corporate updates

Product Recall Support

Michigan’s relatively new medical cannabis market has already experienced recalls due to contamination. In February 2019, the state recalled six batches—or more than 50 pounds—of medical marijuana available on the state’s regulated market since January. The caregiver grown product was contaminated with chemical residue, E. coli, arsenic, cadmium and Salmonella—all potentially dangerous to an already-vulnerable patient population.

These problems aren’t limited to the United States. As more countries implement legal cannabis programs, there has been a struggle to craft cultivation and testing standards that are effective in preventing contamination issues. Even Health Canada continues to issue product recalls on a regular basis despite the country having one of the most advanced cannabis regulatory frameworks in the world.

While quality assurance testing is instrumental to avoiding these issues, there will always be contaminated product that slips through the cracks since it’s impossible to test every single product. Traceability solutions can help immediately recall tainted products and even alert specific patients or consumers that they may have purchased tainted products. That way, the damage is minimized and solutions can be found to avoid future problems.

Click here to receive an investor fact sheet and corporate updates

Leading Traceability Solution

Helix TCS’ BioTrackTHC has become the clear market leader in providing traceability solutions. Upon propagation, each plant or clone is assigned a unique 16-digit identifier that records and archives the plant’s phases, additives, and employee interactions through maturity. At harvest, each batch of cannabis is assigned a new identifier that contains the plant history since propagation and includes pre-packaged goods or derivatives (e.g., oils).

Cannabis batches undergo independent testing and a detailed manifest is prepared prior to transporting the cannabis between licensed businesses. BioTrackTHC also integrates with hardware for patient ID printing and sales limitations that can be easily validated in real-time using the system.

Regulatory agencies and law enforcement in some states can access a secure, online portal to track cannabis transportation and inventory in real-time. Detailed financial reports can also be generated for the Department of Revenue or other agencies responsible for taxation. This ensures that cannabis companies are compliant with chain of custody requirements, as well as held responsible for paying their fair share of taxes.

Click here to receive an investor fact sheet and corporate updates

Expanding into New Markets

Helix TCS Inc.(OTCQB: HLIX) has already become a leader in providing traceability solutions to both U.S. states and international markets. With over 2,000 customers in 34 states and six countries, the company’s traceability and point of sale technology has processed over $18 billion in cannabis sales. The company continues to expand its presence with new agreements in international markets, as well as expansion in domestic markets.

In March alone, the company deployed North Dakota’s Government Cannabis Traceability Program, which uses BioTrackTHC to trace the state’s entire medical cannabis supply chain for compliance and regulatory oversight; extended its contract with Hawaii for one-year to power the state’s cannabis traceability program; and, extended its agreement with Delaware to power the state’s medical cannabis traceability system for two years.

Investors may want to take note of these trends, as the company continues to cultivate its leadership position in traceability solutions for the cannabis industry worldwide. For more information, visit the company’s website at www.helixtcs.com

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading